Interestingly, when treatment was terminated, the kinetics of tumor relapse was significantly lower in Ru1 plus gemcitabine versus gemcitabine alone groups (Fig. 4D-G), suggesting more effective elimination of the PaCSC population when Ru1 was used. This evidence concerns the gene SFMBT1 and neoplasm.